Cargando…

The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study

BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Fan, Xi, Yue-Ling, Wang, Ying, Li, Bi-Ru, Qian, Juan, Ren, Hong, Zhang, Jian, Tang, Hong-Zhi, Ning, Bo-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039791/
https://www.ncbi.nlm.nih.gov/pubmed/33850805
http://dx.doi.org/10.21037/tp-20-230
_version_ 1783677669333794816
author Yin, Fan
Xi, Yue-Ling
Wang, Ying
Li, Bi-Ru
Qian, Juan
Ren, Hong
Zhang, Jian
Tang, Hong-Zhi
Ning, Bo-Tao
author_facet Yin, Fan
Xi, Yue-Ling
Wang, Ying
Li, Bi-Ru
Qian, Juan
Ren, Hong
Zhang, Jian
Tang, Hong-Zhi
Ning, Bo-Tao
author_sort Yin, Fan
collection PubMed
description BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 severe sepsis/septic shock patients admitted to intensive care unit of Shanghai Children’s Medical Center between January 2015 and November 2019. Patients were followed up for the development of ventilation support, the use of vasoactive drugs, continuous renal replacement therapy (CRRT) procedure, and mortality. Biomarkers that reflect the level of inflammation in severe sepsis/septic shock patients with neutropenia were compared to that in patients without neutropenia. RESULTS: Of 141 patients enrolled, 54 patients suffered from severe sepsis/septic shock with severe neutropenia. In patients with severe sepsis/septic shock, severe neutropenia as a complication was an independent risk factor for the use of vasoactive drugs (RR 9.796; 95% CI: 3.774, 25.429; P<0.001), but not for ventilation support (RR 0.157; 95% CI: 0.06, 0.414; P<0.001), CRRT procedure (RR 1.032; 95% CI: 0.359, 2.969; P=0.953) or 28-day mortality (RR 1.405; 95% CI: 0.533, 3.708; P=0.492). Severe sepsis/septic patients with severe neutropenia had a higher plasma level of the following biomarkers: c-reaction protein (CRP) (180.5 vs. 121 mg/mL, P<0.001), procalcitonin (PCT) (12.15 vs. 2.7 ng/mL; P=0.005), interleukin (IL)-6 (316.83 vs. 55.77 pg/mL, P<0.001), IL-10 (39.165 vs. 10.09 pg/mL, P<0.001), interferon (IFN)-γ (6.155 vs. 3.71 pg/mL, P=0.016), and the percentage of regulatory T cells (Tregs) (2.7% vs. 2.09%, P=0.003). Based on the receiver operating characteristic curves, IL-10 exhibited high specificity (79.4%) in evaluating the prognosis of septic patients with neutropenia. CONCLUSIONS: In patients with severe sepsis/septic shock, being complicated with severe neutropenia is associated with higher proportion of using vasoactive drugs, and those patients tend to have higher plasma levels of IL-6, IL-10, IFN-γ and percentage of Treg.
format Online
Article
Text
id pubmed-8039791
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-80397912021-04-12 The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study Yin, Fan Xi, Yue-Ling Wang, Ying Li, Bi-Ru Qian, Juan Ren, Hong Zhang, Jian Tang, Hong-Zhi Ning, Bo-Tao Transl Pediatr Original Article BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 severe sepsis/septic shock patients admitted to intensive care unit of Shanghai Children’s Medical Center between January 2015 and November 2019. Patients were followed up for the development of ventilation support, the use of vasoactive drugs, continuous renal replacement therapy (CRRT) procedure, and mortality. Biomarkers that reflect the level of inflammation in severe sepsis/septic shock patients with neutropenia were compared to that in patients without neutropenia. RESULTS: Of 141 patients enrolled, 54 patients suffered from severe sepsis/septic shock with severe neutropenia. In patients with severe sepsis/septic shock, severe neutropenia as a complication was an independent risk factor for the use of vasoactive drugs (RR 9.796; 95% CI: 3.774, 25.429; P<0.001), but not for ventilation support (RR 0.157; 95% CI: 0.06, 0.414; P<0.001), CRRT procedure (RR 1.032; 95% CI: 0.359, 2.969; P=0.953) or 28-day mortality (RR 1.405; 95% CI: 0.533, 3.708; P=0.492). Severe sepsis/septic patients with severe neutropenia had a higher plasma level of the following biomarkers: c-reaction protein (CRP) (180.5 vs. 121 mg/mL, P<0.001), procalcitonin (PCT) (12.15 vs. 2.7 ng/mL; P=0.005), interleukin (IL)-6 (316.83 vs. 55.77 pg/mL, P<0.001), IL-10 (39.165 vs. 10.09 pg/mL, P<0.001), interferon (IFN)-γ (6.155 vs. 3.71 pg/mL, P=0.016), and the percentage of regulatory T cells (Tregs) (2.7% vs. 2.09%, P=0.003). Based on the receiver operating characteristic curves, IL-10 exhibited high specificity (79.4%) in evaluating the prognosis of septic patients with neutropenia. CONCLUSIONS: In patients with severe sepsis/septic shock, being complicated with severe neutropenia is associated with higher proportion of using vasoactive drugs, and those patients tend to have higher plasma levels of IL-6, IL-10, IFN-γ and percentage of Treg. AME Publishing Company 2021-03 /pmc/articles/PMC8039791/ /pubmed/33850805 http://dx.doi.org/10.21037/tp-20-230 Text en 2021 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yin, Fan
Xi, Yue-Ling
Wang, Ying
Li, Bi-Ru
Qian, Juan
Ren, Hong
Zhang, Jian
Tang, Hong-Zhi
Ning, Bo-Tao
The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title_full The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title_fullStr The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title_full_unstemmed The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title_short The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
title_sort clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039791/
https://www.ncbi.nlm.nih.gov/pubmed/33850805
http://dx.doi.org/10.21037/tp-20-230
work_keys_str_mv AT yinfan theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT xiyueling theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT wangying theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT libiru theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT qianjuan theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT renhong theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT zhangjian theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT tanghongzhi theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT ningbotao theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT yinfan clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT xiyueling clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT wangying clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT libiru clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT qianjuan clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT renhong clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT zhangjian clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT tanghongzhi clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy
AT ningbotao clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy